Recent News
On August 4, 2025 Agios announced regulatory approval of PYRUKYND (mitapivat) for adults with thalassemia in Saudi Arabia, extending the drug’s commercial footprint in the Gulf Cooperation Council region.
Technical Analysis
ADX at 12.9 indicates no established trend; directional movement indicators therefore imply rangebound price action rather than a clear trend. The lack of trend strength links directly to a valuation profile that currently reads as under-valued while price seeks a clearer directional bias.
DI+ registered a peak-and-reversal while DI- shows a decreasing path; the pair signals short-term bearish pressure from the positive directional index’ reversal even as the decreasing negative index partially offsets that pressure. The mixed directional indicator signals support a sideways-to-lower short-term bias rather than sustained selling pressure.
MACD shows a peak-and-reversal pattern and recent readings align with bearish momentum: the MACD has turned down from its prior peak and sits close to the signal line, indicating momentum faded and downward pressure on shorter-term momentum. That deterioration increases the chance of corrective moves even though broader valuation drivers remain intact.
MRO reads negative at -23.2, which implies the current price sits below its modeled target and therefore carries technical potential to increase toward that target; the negative oscillator indicates upside potential from a regression-to-target perspective, a corrective force that counters the momentum deterioration.
RSI near 52 with a peak-and-reversal profile points to a momentum top rather than oversold or overbought extremes; the indicator suggests limited conviction behind immediate directional moves and supports a continuation of choppy trading until a catalyst changes momentum.
Price sits roughly between short- and medium-term averages: price close $36.61, 20-day average $36.90 and 50-day average $37.51 while the 200-day average sits at $34.17. Short-term EMAs (12/26) around $37.21–$37.22 sit above the close, and the 12-day EMA displays a peak-and-reversal—collectively pointing to mild short-term resistance and a bias for consolidation above the 200-day average rather than rapid appreciation.
Bollinger band mid-range places the stock near the lower half of its recent volatility band (lower 1x $36.04; upper 1x $37.76), while the SuperTrend upper level at $39.46 represents a material near-term resistance band. Ichimoku conversion and base lines (Tenkan $36.96; Kijun $36.90) both lie above the close, reinforcing near-term resistance into the averages. Lower-than-average volume versus 10/50/200‑day averages signals limited conviction behind recent moves, increasing the likelihood of rangebound trade punctuated by catalyst-driven spikes.
Fundamental Analysis
Revenue for the period totaled $12,455,000 with revenue growth listed as 42.73% and a year-over-year revenue growth figure of 721.49%; quarter-over-quarter revenue change shows -328.81%. The YoY and QoQ readings point to substantial calendar comparisons and short-term quarter-to-quarter variability; revenue expansion on an annual basis supports a constructive fundamental backdrop even as sequential volatility appears.
Gross margin stands at 86.34%, indicating strong product-level economics. Operating and EBIT margins sit negative at -10.20%, reflective of continued investment in R&D and commercialization; EBIT of -$127,056,000 and EBITDA of -$125,797,000 underline ongoing operating losses tied to development and early commercial activity.
EPS came in at -$1.93 versus an estimate of -$1.75, producing an EPS surprise ratio of -10.29% (EPS difference -$0.18). The negative EPS aligns with operating losses but cash metrics mitigate near-term solvency concerns.
Cash and short-term investments total $938,937,000 and free cash flow was negative at -$87,999,000; the company carries a large liquidity buffer that supports development spending and potential commercialization plans. Current ratio at 14.48 and quick ratio at 14.04 reflect an unusually strong short-term liquidity position relative to current liabilities.
Return metrics remain negative: return on equity -8.18% and return on assets -7.40%, consistent with a company in an investment phase. Earnings growth shows positive momentum at 24.52% and earnings growth QoQ of 220.93%, signaling accelerating earnings dynamics from low base levels.
Valuation multiples show contrasts: price-to-book 1.54 sits well below the industry peer mean of 5.29 and industry peer median of 6.29; price-to-sales at 169.18 stands above the industry peer mean of 56.01 and median of 19.71; PE at -18.27 sits between the industry peer mean of -11.16 and industry peer median of -19.27. The operating margin at -10.20% sits below the industry peer mean of -0.73% and the industry peer median of 0.24%, indicating weaker near-term profitability versus peer central tendencies. These relative positions highlight a mixed valuation picture: strong liquidity and R&D investment alongside high revenue multiple metrics driven by low current revenue base. (Industry peer mean/median/range values used where provided.)
WMDST values the stock as under-valued given the company’s cash cushion of $938.94M, high gross margin, and pipeline optionality despite current operating losses and an elevated price-to-sales multiple. The valuation assessment weighs liquidity and product approvals more heavily than near-term EPS losses.
MOST-RECENT QUARTERLY REPORT
| REPORT PERIOD ENDING: | 2025-06-30 |
| REPORT DATE: | 2025-07-31 |
| NEXT REPORT DATE: | 2025-10-30 |
| CASH FLOW | Begin Period Cash Flow | $ 79.0 M |
| Operating Cash Flow | $ -77.12 M | |
| Capital Expenditures | $ -10.88 M | |
| Change In Working Capital | $ 8.3 M | |
| Dividends Paid | — | |
| Cash Flow Delta | $ 1.9 M | |
| End Period Cash Flow | $ 80.9 M | |
| INCOME STATEMENT | REVENUE | |
| Total Revenue | $ 12.5 M | |
| Forward Revenue | $ 2.5 M | |
| COSTS | ||
| Cost Of Revenue | $ 1.7 M | |
| Depreciation | $ 1.3 M | |
| Depreciation and Amortization | $ 1.3 M | |
| Research and Development | $ 91.9 M | |
| Total Operating Expenses | $ 139.5 M | |
| PROFITABILITY | ||
| Gross Profit | $ 10.8 M | |
| EBITDA | $ -125.80 M | |
| EBIT | $ -127.06 M | |
| Operating Income | $ -127.06 M | |
| Interest Income | $ 14.5 M | |
| Interest Expense | — | |
| Net Interest Income | $ 14.5 M | |
| Income Before Tax | $ -112.02 M | |
| Tax Provision | — | |
| Tax Rate | — | |
| Net Income | $ -112.02 M | |
| Net Income From Continuing Operations | $ -112.02 M | |
| EARNINGS | ||
| EPS Estimate | $ -1.75 | |
| EPS Actual | $ -1.93 | |
| EPS Difference | $ -0.18 | |
| EPS Surprise | -10.286 % | |
| Forward EPS | $ -1.52 | |
| BALANCE SHEET | ASSETS | |
| Total Assets | $ 1.5 B | |
| Intangible Assets | — | |
| Net Tangible Assets | $ 1.4 B | |
| Total Current Assets | $ 1.0 B | |
| Cash and Short-Term Investments | $ 938.9 M | |
| Cash | $ 80.9 M | |
| Net Receivables | $ 5.0 M | |
| Inventory | $ 30.8 M | |
| Long-Term Investments | $ 3.9 M | |
| LIABILITIES | ||
| Accounts Payable | $ 17.5 M | |
| Short-Term Debt | — | |
| Total Current Liabilities | $ 70.4 M | |
| Net Debt | — | |
| Total Debt | $ 48.8 M | |
| Total Liabilities | $ 101.7 M | |
| EQUITY | ||
| Total Equity | $ 1.4 B | |
| Retained Earnings | $ -350.23 M | |
| VALUATION & PER-SHARE METRICS | EQUITY & PER-SHARE METRICS | |
| Book Value Per-Share | $ 23.60 | |
| Shares Outstanding | 58.039 M | |
| Revenue Per-Share | $ 0.21 | |
| VALUATION | Market Capitalization | $ 2.1 B |
| Enterprise Value | $ 1.2 B | |
| Enterprise Multiple | -9.674 | |
| Enterprise Multiple QoQ | 5.127 % | |
| Enterprise Multiple YoY | -45.507 % | |
| Enterprise Multiple IPRWA | high: 47.216 median: 14.143 mean: 5.461 AGIO: -9.674 low: -68.907 |
|
| EV/R | 97.707 | |
| CAPITAL STRUCTURE | ||
| Asset To Equity | 1.074 | |
| Asset To Liability | 14.469 | |
| Debt To Capital | 0.034 | |
| Debt To Assets | 0.033 | |
| Debt To Assets QoQ | -2.615 % | |
| Debt To Assets YoY | -19.23 % | |
| Debt To Assets IPRWA | high: 0.995 mean: 0.195 median: 0.062 AGIO: 0.033 low: 0.0 |
|
| Debt To Equity | 0.036 | |
| Debt To Equity QoQ | -1.385 % | |
| Debt To Equity YoY | -25.864 % | |
| Debt To Equity IPRWA | high: 1.577 mean: 0.256 median: 0.059 AGIO: 0.036 low: -1.039 |
|
| PRICE-BASED VALUATION | ||
| Price To Book (P/B) | 1.539 | |
| Price To Book QoQ | 24.667 % | |
| Price To Book YoY | -57.452 % | |
| Price To Book IPRWA | high: 16.592 median: 6.295 mean: 5.287 AGIO: 1.539 low: -10.064 |
|
| Price To Earnings (P/E) | -18.266 | |
| Price To Earnings QoQ | -9.445 % | |
| Price To Earnings YoY | -26.49 % | |
| Price To Earnings IPRWA | high: 44.732 mean: -11.163 AGIO: -18.266 median: -19.271 low: -73.374 |
|
| PE/G Ratio | -0.745 | |
| Price To Sales (P/S) | 169.179 | |
| Price To Sales QoQ | -18.434 % | |
| Price To Sales YoY | -38.977 % | |
| Price To Sales IPRWA | high: 517.227 AGIO: 169.179 mean: 56.006 median: 19.711 low: 0.25 |
|
| FORWARD MULTIPLES | ||
| Forward P/E | -21.116 | |
| Forward PE/G | -0.861 | |
| Forward P/S | 859.293 | |
| EFFICIENCY | OPERATIONAL | |
| Operating Leverage | 0.448 | |
| ASSET & SALES | ||
| Asset Turnover Ratio | 0.008 | |
| Asset Turnover Ratio QoQ | 51.845 % | |
| Asset Turnover Ratio YoY | -22.505 % | |
| Asset Turnover Ratio IPRWA | high: 0.388 mean: 0.115 median: 0.113 AGIO: 0.008 low: -0.001 |
|
| Receivables Turnover | 2.99 | |
| Receivables Turnover Ratio QoQ | 27.707 % | |
| Receivables Turnover Ratio YoY | 25.222 % | |
| Receivables Turnover Ratio IPRWA | high: 7.487 AGIO: 2.99 median: 1.422 mean: 1.405 low: 0.012 |
|
| Inventory Turnover | 0.056 | |
| Inventory Turnover Ratio QoQ | 48.497 % | |
| Inventory Turnover Ratio YoY | -11.476 % | |
| Inventory Turnover Ratio IPRWA | high: 2.946 mean: 0.607 median: 0.415 AGIO: 0.056 low: 0.006 |
|
| Days Sales Outstanding (DSO) | 30.514 | |
| CASH CYCLE | ||
| Cash Conversion Cycle Days (CCC) | 1258.184 | |
| Cash Conversion Cycle Days QoQ | 24.414 % | |
| Cash Conversion Cycle Days YoY | -34.362 % | |
| Cash Conversion Cycle Days IPRWA | AGIO: 1258.184 high: 1140.813 median: 205.05 mean: 199.778 low: -1350.846 |
|
| CAPITAL DEPLOYMENT | ||
| Cash Conversion Ratio | 0.013 | |
| CapEx To Revenue | -0.873 | |
| CapEx To Depreciation | -8.638 | |
| CAPITAL, LIQUIDITY & COVERAGE | CAPITAL STRUCTURE | |
| Total Capital | $ 1.4 B | |
| Net Invested Capital | $ 1.4 B | |
| Invested Capital | $ 1.4 B | |
| Net Tangible Assets | $ 1.4 B | |
| Net Working Capital | $ 949.1 M | |
| LIQUIDITY | ||
| Cash Ratio | 13.335 | |
| Current Ratio | 14.479 | |
| Current Ratio QoQ | -21.723 % | |
| Current Ratio YoY | 43.471 % | |
| Current Ratio IPRWA | high: 24.698 AGIO: 14.479 mean: 3.927 median: 2.52 low: 0.021 |
|
| Quick Ratio | 14.041 | |
| Quick Ratio QoQ | -21.698 % | |
| Quick Ratio YoY | 44.606 % | |
| Quick Ratio IPRWA | AGIO: 14.041 high: 10.544 mean: 2.947 median: 2.158 low: 0.021 |
|
| COVERAGE & LEVERAGE | ||
| Debt To EBITDA | -0.388 | |
| Cost Of Debt | 0.018 % | |
| Interest Coverage Ratio | -12705.6 | |
| Interest Coverage Ratio QoQ | 19.157 % | |
| Interest Coverage Ratio YoY | 20.071 % | |
| Interest Coverage Ratio IPRWA | high: 677.4 mean: 35.794 median: 2.347 low: -1465.352 AGIO: -12705.6 |
|
| Operating Cash Flow Ratio | -1.56 | |
| TIMING / LIQUIDITY | ||
| Days Payables Outstanding (DPO) | 1314.421 | |
| DIVIDENDS | ||
| Dividend Coverage Ratio | — | |
| Dividend Payout Ratio | — | |
| Dividend Rate | — | |
| Dividend Yield | — | |
| PERFORMANCE | GROWTH | |
| Asset Growth Rate | -5.418 % | |
| Revenue Growth | 42.734 % | |
| Revenue Growth QoQ | -328.805 % | |
| Revenue Growth YoY | 721.492 % | |
| Revenue Growth IPRWA | high: 303.4 % AGIO: 42.734 % mean: 20.731 % median: 12.272 % low: -259.856 % |
|
| Earnings Growth | 24.516 % | |
| Earnings Growth QoQ | 220.932 % | |
| Earnings Growth YoY | 48.115 % | |
| Earnings Growth IPRWA | high: 155.0 % AGIO: 24.516 % median: 11.33 % mean: 2.342 % low: -181.25 % |
|
| MARGINS | ||
| Gross Margin | 86.335 % | |
| Gross Margin QoQ | -1.406 % | |
| Gross Margin YoY | 4.462 % | |
| Gross Margin IPRWA | high: 100.0 % AGIO: 86.335 % median: 80.103 % mean: 77.812 % low: -77.751 % |
|
| EBIT Margin | -1020.12 % | |
| EBIT Margin QoQ | -16.518 % | |
| EBIT Margin YoY | -16.948 % | |
| EBIT Margin IPRWA | high: 338.783 % median: 23.755 % mean: -73.269 % AGIO: -1020.12 % low: -5123.44 % |
|
| Return On Sales (ROS) | -1020.12 % | |
| Return On Sales QoQ | -16.518 % | |
| Return On Sales YoY | -16.948 % | |
| Return On Sales IPRWA | high: 89.247 % median: 28.85 % mean: -77.094 % AGIO: -1020.12 % low: -5698.0 % |
|
| CASH FLOW | ||
| Free Cash Flow (FCF) | $ -88.00 M | |
| Free Cash Flow Yield | -4.176 % | |
| Free Cash Flow Yield QoQ | -32.667 % | |
| Free Cash Flow Yield YoY | 37.098 % | |
| Free Cash Flow Yield IPRWA | high: 36.371 % median: 0.516 % mean: -0.331 % AGIO: -4.176 % low: -74.318 % |
|
| Free Cash Growth | -21.608 % | |
| Free Cash Growth QoQ | 32.475 % | |
| Free Cash Growth YoY | -20.731 % | |
| Free Cash Growth IPRWA | high: 165.621 % median: 13.562 % mean: 3.76 % AGIO: -21.608 % low: -193.262 % |
|
| Free Cash To Net Income | 0.786 | |
| Cash Flow Margin | -881.895 % | |
| Cash Flow To Earnings | 0.981 | |
| VALUE & RETURNS | ||
| Economic Value Added | — | |
| Return On Assets (ROA) | -7.402 % | |
| Return On Assets QoQ | 33.417 % | |
| Return On Assets YoY | -37.515 % | |
| Return On Assets IPRWA | high: 36.544 % median: 1.616 % mean: -1.367 % AGIO: -7.402 % low: -68.545 % |
|
| Return On Capital Employed (ROCE) | -9.07 % | |
| Return On Equity (ROE) | -0.082 | |
| Return On Equity QoQ | 34.346 % | |
| Return On Equity YoY | -43.795 % | |
| Return On Equity IPRWA | high: 1.117 median: 0.04 mean: 0.008 AGIO: -0.082 low: -1.572 |
|
| DuPont ROE | -7.9 % | |
| Return On Invested Capital (ROIC) | — | |
| Return On Invested Capital QoQ | — | |
| Return On Invested Capital YoY | — | |
| Return On Invested Capital IPRWA | — | |